No Data
Kemei Diagnostics (688468.SH): Has not yet deployed the related Business of DeepSeek.
Gelonghui reported on March 20 that Kemei Diagnostics (688468.SH) stated on the interactive platform that the company has not yet deployed the DeepSeek related Business. The company is closely monitoring the development trends of domestic AI large models and actively exploring their application potential in vertical Industries.
Kemei Diagnostics (688468.SH): Currently collaborating with the Rui Jin Hospital Clinical Endocrinology Laboratory and the Shanghai Clinical Laboratory Center.
On March 20, Gelonghui reported that Kemei Diagnosis (688468.SH) stated on the interactive platform that the company is currently collaborating with the Ruijin Hospital Clinical Endocrinology Laboratory and the Shanghai Clinical Testing Center to develop a standardized方案 and key algorithms for the thyroid disease testing indicators FT3 and FT4, promoting the mutual recognition of their results. FT3 and FT4 are important references for the diagnosis and treatment of thyroid diseases in clinical practice. Currently, this tripartite cooperation project is in its mid-term phase, focusing on sample collection and the development of key algorithms, with a completion expected in the first quarter of 2025.
Komei Diagnosis: Komei Diagnostic Technology Co., Ltd. 2024 Annual Performance Report Announcement
Kemei Diagnostics (688468.SH): The net income for the fiscal year 2024 is 0.127 billion yuan, a decrease of 13.83% year-on-year.
On February 27, Glory Financial reported that Kemei Diagnostics (688468.SH) released its performance preliminary report for 2024. During the reporting period, the company achieved revenue of 436.2898 million yuan, a decrease of 2.03% compared to the same period last year; operating profit of 134.7509 million yuan, a decline of 18.96% compared to the same period last year; total profit of 137.8276 million yuan, a decrease of 17.03% compared to the same period last year; net income attributable to the parent company's owners of 126.9928 million yuan, a decrease of 13.83% compared to the same period last year; net income attributable to the parent company's owners after deducting non-recurring gains and losses of 10,0.
Chemclin Diagnostics Co., Ltd. (SHSE:688468) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Market Cap Surged CN¥446m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Business And Shares Still Trailing The Market
